Predictive Value of Inflammatory Biomarkers and FEV1 for COPD

Peking University First Hospital10,385 enrolled

Overview

This is a multi-center, prospective, cohort study. A total of 10,000 people aged 40～75 without lung disease will be recruited and followed for 3 years. By measure the rate of decline in forced expiratory volume at one second（FEV1） and baseline inflammatory biomarkers in exhaled breath condensate and peripheral blood, we aim to explore the predictive model for chronic obstructive pulmonary disease（COPD） in China.

This is a multi-center, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. The Department of Respiratory and Critical Care of Peking University First Hospital is responsible for this research. Other 9 units participating in the study, include the The Second Hospital of Hebei Medical University, Henan Provincial People's Hospital, The Second Hospital of Jilin University, The First Affiliated Hospital of Xi'an Jiaotong University, Shandong Provincial Hospital Affiliated to Shandong University,Shanxi Dayi Hospital, Tianjin Medical University General Hospital, The Affiliated Hospital of Inner Mongolia Medical University,The First Hospital of Qinhuangdao. Some questionnaire such as St George's Respiratory Questionnaire (SGRQ), income class, educational level, comorbidity, smoking habit and biomass smoke exposure history will be collected. The baseline level of Interleukin 6 (IL-6), high-sensitivity C-reactive Protein (hs-CRP), microRNAs-23a (miR-23a) in peripheral blood and pH value in exhaled breath condensate (EBC) will be measured, lung spirometry will be tested in the first, second and fourth years. Primary outcome is the incidence of COPD, multivariate regression analysis will be used to establish the predictive model for COPD in China. The study protocol has been approved by the Peking University First Hospital Institutional Review Board (IRB) (2018-31). Any protocol modifications will be submitted for the IRB review and approval.

Study Type

OBSERVATIONAL

Enrollment

10,385

Conditions

COPD FEV1

Interventions

No interventionOTHER

This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.

Eligibility

Sex: ALLMin age: 40 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. aged at 40-75 years old; 2. FEV1/FVC\>70% after inhaled bronchodilator 3. have willing to participate in this study, follow the research program and have the ability to sign the informed consent; 4. lived in a community for more than 1 years and has no plans to move out in the next 4 years 5. can be contacted Exclusion Criteria: 1. history of asthma, COPD, lung cancer, active pulmonary tuberculosis, bronchiectasis, diffuse lung disease (interstitial pneumonia, pulmonary sarcoidosis, occupational lung disease, sarcoidosis et al) and pleural disease; 2. history of lobectomy and / or lung transplantation; 3. predicted life expectancy less than 3 years; 4. history of severe psychiatric illnesses, mental disorders, neurological disorders, malignant tumors, chronic liver disease, heart failure, autoimmune diseases, chronic kidney disease; 5. Alcoholism, drug abuse or abuse of toxic solvents; 6. Cannot finish long term follow-up or poor compliance; 7. Do not provide consent

Locations (10)

Peking University First Hospital

Beijing, Beijing Municipality, China

The First Hospital of Qinhuangdao

Qinhuangdao, Hebei, China

The Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Outcomes

Primary Outcomes

The incidence of COPD in the second and fourth year and the association between incidence of COPD and rapid decline of FEV1.

FEV1/FVC(forced vital capacity)\<70% (after bronchial dilation test);Detect the decline of FEV1(%)by Vitalograph COPD6.

Time frame: 4 years

Secondary Outcomes

The association between incidence of COPD and the air pollution level in different provinces in China.

Record data of air pollution in different provinces in China from the environmental monitoring website. And analyze the correlation between the COPD incidence and air pollution level.

Time frame: 4 years

The association between incidence of COPD and different comorbidity condition, such as metabolic syndrome, cardiovascular disease.

Record comorbidity condition data of human subjects, and then analyze the correlation between the COPD incidence and different comorbidity condition.

Time frame: 4 years

The mean decline rate of FEV1

Monitor pulmonary function decline in the second and the fourth year, then calculate the mean decline value.

Time frame: 4 years

The association between decline rate of FEV1 and air pollution level

Record data of air pollution in different provinces in China from the environmental monitoring website. And analyze the correlation between the decline rate of FEV1 and air pollution level.

Time frame: 4 years

The correlation between the incidence of COPD and serum IL-6 level.

Detect the serum IL-6 levels(ng/L), then analyze the correlation between the IL-6 levels and COPD incidence.

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.